Research
Hormonal
Insulin resistance in skeletal muscle and adipose tissue, characterized by impaired GLUT4 translocation, is a primary driver of whole-body hyperglycemia and type 2 diabetes.
Maintaining insulin sensitivity through regular physical activity (which stimulates GLUT4 translocation independently of insulin) and managing body fat levels are critical for preventing the transition from insulin resistance to type 2 diabetes.
StrongSupportsHIGH confidence
Reduced glucose transport activity results in aberrant use of energy substrates and is associated with insulin resistance and type 2 diabetes. It is well established that... GLUT4, the workhorse in insulin- and contraction-stimulated glucose uptake in skeletal muscle, are critical contributors in the control of whole-body glycemia.
Why this rating
The paper is a comprehensive review citing extensive genetic, molecular, and clinical evidence.
Source
Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease
Alexandra Chadt et al. · Pflügers Archiv - European Journal of Physiology · 2020
DOI 10.1007/s00424-020-02417-x
narrative_reviewCited 487×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High dietary fructose intake promotes non-alcoholic fatty liver disease (NAFLD) and hepatic insulin resistance by stimulating de novo lipogenesis via GLUT2 and GLUT5 transporters.Strong
- Hepatic insulin resistance, characterized by failure to suppress hepatic glucose production (gluconeogenesis and glycogenolysis), is a major feature of type 2 diabetes pathophysiology.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →